2096455-90-0
物理化學(xué)性質(zhì)
報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
2024/11/08 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 5mg | 800元 |
2024/11/08 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 10mM * 1mLin DMSO | 880元 |
2024/11/08 | HY-19705B | 2096455-90-0 Adriforant hydrochloride | 2096455-90-0 | 10mg | 1200元 |
常見問題列表
Ki: 2.4 nM (H4R bind), 1.56 nM (H4R func)
Adriforant is tested and observed binding K i =2.4 nM and functional K i =1.56 nM for H4R. Data from functional assays produce convergent projections of the free plasma efficacious concentration and Adriforant (Compound 13) is fast on/fast off on rhH4R. The in vitro IC 50 on human native isolated eosinophils assessing actin polymerisation is 1.16 nM and assuming need 10 times the IC 50 for >90% receptor occupancy (and therefore near complete inhibition of the response) suggested a concentration of 12 nM. The data in the whole blood GAFS assay demonstrates that the imetit induced shape change is completely blocked at a total blood concentration of 30 nM (which correcting for PPB and blood partitioning equates to approximately 10 nM free). For the purpose of dose projection and safety margin calculation, a Ceff/Cmin concentration of 10-15 nM is used.